<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04876430</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0401</org_study_id>
    <nct_id>NCT04876430</nct_id>
  </id_info>
  <brief_title>Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems</brief_title>
  <acronym>ABOVE</acronym>
  <official_title>Open-label Randomized Clinical Trial Comparing Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With Minimal Inhibitory Concentrations for Meropenem Above 32mg/L</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Enterobacterales resistant to carbapenem are cause of severe concern in hospital-acquired&#xD;
      infections since therapeutic options are limited. Recently approved drugs, such as&#xD;
      bela-lactam/beta-lactamase inhibitor, have been the drug of choice. However, its use is&#xD;
      limited in low- and middle-income countries. Thus, therapy of these infections mostly relies&#xD;
      on polymyxins and other old drugs.&#xD;
&#xD;
      The role of adjuvant carbapenem therapy in combination with polymyxins, aminoglycosides and&#xD;
      other drugs is under investigation. From a pharmacokinetic/pharmacodynamic (PK/PD), there is&#xD;
      an elevated probability that high-dose, extended infusion administered meropenem reach the&#xD;
      PK/PD target of 40% above the minimal inhibitory concentration (MIC) of the pathogen when the&#xD;
      MIC is 32mg/L or lower (non-susceptible isolates have MICs of 4mg/L or higher). However, the&#xD;
      MIC is not routinely determined in clinical laboratories. In addition, high-level (above&#xD;
      32mg/L) resistance to carbapenems have been reported in many studies.&#xD;
&#xD;
      This open-label, randomized clinical trial aim to assess if the addition of meropenem to the&#xD;
      best available therapy can increase the number of days alive and free of hospitalization in&#xD;
      patients with bloodstream infections by Enterobacterales with MIC of meropenem above 32mg/L.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Anticipated">June 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 3, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days alive and free of hospitalization</measure>
    <time_frame>60 days</time_frame>
    <description>Number of days in which patients are alive and out of the hospital</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>14, 28 and 60 days after randomization</time_frame>
    <description>Death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antimicrobial-free days</measure>
    <time_frame>60 days after randomization</time_frame>
    <description>Number of days in which patients are alive and without use of antimicrobial drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse of infection</measure>
    <time_frame>60 days after randomization</time_frame>
    <description>Presence of infection with isolation of the same bacteria between 14 and 60 days after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clostridioides difficile infection</measure>
    <time_frame>60 days after randomization</time_frame>
    <description>Incidence of Clostridioides difficile infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>14 days after randomization</time_frame>
    <description>Incidence of Acute Kidney Injury, according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meropenem-related adverse effects</measure>
    <time_frame>14 days after randomization</time_frame>
    <description>Incidence of adverse effects related to meropenem, such as neurological toxicity and hypersensitivity reactions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Carbapenem-Resistant Enterobacteriaceae Infection</condition>
  <condition>Bloodstream Infection</condition>
  <arm_group>
    <arm_group_label>Meropenem plus Best Available Therapy plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meropenem 2g every 8 hours combined with the best available therapy (BAT). BAT will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.&#xD;
Polymyxin B or colistimethate;&#xD;
Amikacin or gentamicin;&#xD;
Tigecycline;&#xD;
Another antimicrobial with in vitro susceptibility.&#xD;
Doses will be defined by the assistant team.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Available Therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The best available therapy will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.&#xD;
Polymyxin B or colistimethate;&#xD;
Amikacin or gentamicin;&#xD;
Tigecycline;&#xD;
Another antimicrobial with in vitro susceptibility.&#xD;
Doses will be defined by the assistant team.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Meropenem 2g every 8h for patients with glomerular filtration rate (GFR) equal or higher that 50 mL/min. Dose adjustment is recommended for patients with GFR &lt; 50mL/min.</description>
    <arm_group_label>Meropenem plus Best Available Therapy plus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary or secondary bloodstream infections by any specie of the Enterobacterales&#xD;
             family with minimum inhibitory concentration (MIC) for meropenem &gt;32mg/L;&#xD;
&#xD;
          -  Agreement of the assistant team with the inclusion of the patient in the study;&#xD;
&#xD;
          -  Agreement by the patient or legal guardian to sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known pregnancy;&#xD;
&#xD;
          -  Patients belonging to the population deprived of their liberty;&#xD;
&#xD;
          -  Known allergy to meropenem;&#xD;
&#xD;
          -  Use of ceftazidime-avibactam (or any other new antimicrobial agent that become&#xD;
             available in Brazil during the study period) for the treatment of the current&#xD;
             infection;&#xD;
&#xD;
          -  Infection by an Enterobacterales isolates without in vitro susceptibility to at least&#xD;
             one antimicrobial drug;&#xD;
&#xD;
          -  Bloodstream co-infection by another gram negative bacilli;&#xD;
&#xD;
          -  Concomitant infection at any site by a pathogen which meropenem is indicated;&#xD;
&#xD;
          -  Neutropenia (&lt;1000 neutrophils cells/mm3)&#xD;
&#xD;
          -  Death expected within 48 hours of eligibility assessment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre P Zavascki, MD, PhD</last_name>
      <phone>51997149578</phone>
      <email>azavascki@hcpa.edu.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90619-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Helena S. P. Rigatto, MD, PhD</last_name>
      <phone>5551992460185</phone>
      <email>mhprigatto@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Clinicas de Porto Alegre</investigator_affiliation>
    <investigator_full_name>Alexandre Prehn Zavascki</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>carbapenem</keyword>
  <keyword>carbapenemase</keyword>
  <keyword>polymyxins</keyword>
  <keyword>treatment</keyword>
  <keyword>carbapenem resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Enterobacteriaceae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

